Funder
AstraZeneca
Berlin-Chemie
Boehringer Ingelheim
Chiesi Pharmaceuticals
InterMune
Teva
Ministry of Education and Science
Chiesi
Genentech
GlaxoSmithKline
Inova Fairfax Health System, Miller Communications, the National Association for Continuing Education
Novartis
Roche
Sunovion
American Thoracic Society
Columbia University
New York University
National Institutes of Health
Merck
Pfizer
Johnson & Johnson
CMC
UK
Subject
Pulmonary and Respiratory Medicine
Reference30 articles.
1. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial;Singh;Lancet (London, Engl),2016
2. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease;Lipson;Am. J. Respir. Crit. Care Med.,2017
3. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial;Vestbo;Lancet (London, Engl),2017
4. Once-daily single-inhaler triple versus dual therapy in patients with COPD;Lipson;N. Engl. J. Med.,2018
5. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial;Papi;Lancet (London, Engl),2018
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献